# AMICUS THERAPEUTICS, INC. (FOLD) — merger/definitive [completed]
Source: SEC API (secapi.ai) · situation sit_fc3582b91d7a74f7d5a7 · retrieved 2026-08-11T16:02:23.760Z

## Overview
Amicus Therapeutics, Inc. is a leading, global biotechnology company with a clear and compelling mission to develop and deliver transformative medicines for people living with rare diseases.

BioMarin Pharmaceutical Inc. agreed to acquire Amicus Therapeutics, Inc. in an all-cash merger pursuant to an Agreement and Plan of Merger dated December 19, 2025. Under the terms of the merger, Merger Sub, a wholly owned subsidiary of BioMarin, will merge with and into Amicus, with Amicus surviving as a wholly owned subsidiary of BioMarin. Each outstanding share of Amicus common stock will be converted into the right to receive $14.50 per share in cash, without interest and subject to applicable tax withholding. The merger is subject to customary closing conditions, including stockholder approval (requiring a majority of outstanding shares as of the January 28, 2026 record date), regulatory approvals under antitrust and foreign direct investment laws, and the absence of a material adverse effect. The transaction is not conditioned on financing, with BioMarin having obtained a $3,650,000,000 senior secured bridge loan commitment. The special meeting of stockholders is scheduled for March 3, 2026, and the merger is expected to close in the second quarter of 2026.

## Terms
- Counterparty: BioMarin Pharmaceutical Inc. · Consideration: cash · Premium: 33.0% · Price/share: $14.5

## Key dates
- Announced 2026-02-02 · Record 2026-01-28 · Vote 2026-03-03 · Expiry 2026-12-19 · Expected close 2026-06-30 · Completed 2026-04-27

## Timeline
- 2026-02-02 · DEFM14A (0001140361-26-003092): DEFM14A - AMICUS THERAPEUTICS, INC. — *Amicus Therapeutics, Inc. is a leading, global biotechnology company with a clear and compelling mission to develop and deliver transformative medicines for people living with rare diseases.* BioMarin Pharmaceutical Inc. agreed to acquire Amicus Therapeutics, Inc. in an all-cash merger pursuant to an Agreement and Plan of Merger dated December 19, 2025. Under the terms of the merger, Merger Sub, a wholly owned subsidiary of BioMarin, will merge with and into Amicus, with Amicus surviving as a wholly owned subsidiary of BioMarin. Each outstanding share of Amicus common stock will be converted into the right to receive $14.50 per share in cash, without interest and subject to applicable tax withholding. The merger is subject to customary closing conditions, including stockholder approval (requiring a majority of outstanding shares as of the January 28, 2026 record date), regulatory approvals under antitrust and foreign direct investment laws, and the absence of a material adverse effect. The transaction is not conditioned on financing, with BioMarin having obtained a $3,650,000,000 senior secured bridge loan commitment. The special meeting of stockholders is scheduled for March 3, 2026, and the merger is expected to close in the second quarter of 2026.
  https://www.sec.gov/Archives/edgar/data/1178879/0001140361-26-003092.txt
- 2026-04-27 · 8-K (0001140361-26-016968): 8-K 8-K
  https://www.sec.gov/Archives/edgar/data/1178879/000114036126016968/ef20071351_8k.htm

## Citations
- 0001140361-26-003092 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000114036126003092
- 0001140361-26-016968 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000114036126016968